We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Pembrolizumab has shown a promising response rate in patients with pre-treated metastatic gastric cancer, according to results from the KEYNOTE-059 trial…